[Antagonists of the type 3 serotonin receptor (5 -HT3) in IBS].
Irritable bowel syndrome (IBS) is a common chronic gastrointestinal (GI) disorder, but its pathophysiology remains unknown. 5-hydroxytryptamine (5-HT, serotonin) is an important neurotransmitter involved in the brain-gut connection. Alosetron, a 5-HT3 receptor antagonist, has been demonstrated in randomized, placebo-controlled trials (RCT) to be effective in diarrhea-predominant IBS(IBS-D). Constipation is the most common adverse event. Alosetron improved abdominal pain and discomfort and stool consistency in both female and male patients, but it did not improve other symptoms (sense of urgency, stool frequency and bloating) in male patients. Although less is known about the gender differences in therapeutic benefit, a new 5-HT3 antagonist, cilansetron, has demonstrated effectiveness in male and female IBS-D patients and is currently under clinical trials.
Komoto
Shunsuke
S
Second Department of Internal Medicine, National Defense Medical College.
Miura
Soichiro
S
D002227:Carbazoles / Q000627:therapeutic use; D002243:Carbolines / Q000627:therapeutic use; D005260:Female; D005765:Gastrointestinal Agents / Q000627:therapeutic use*; D006801:Humans; D043183:Irritable Bowel Syndrome / Q000188:drug therapy*; D008297:Male; D011725:Pyridines / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D058831:Serotonin 5-HT3 Receptor Antagonists
D002227:Carbazoles; D002243:Carbolines; D005765:Gastrointestinal Agents; D011725:Pyridines; D058831:Serotonin 5-HT3 Receptor Antagonists; C090840:alosetron; C084473:cilansetron